U.S. Food and Drug Administration Approves Opdivo® (nivolumab) for the.
The Pharma Data
AUGUST 22, 2021
Food and Drug Administration (FDA) for the adjuvant treatment of patients with urothelial carcinoma (UC) who are at high risk of recurrence after undergoing radical resection, regardless of prior neoadjuvant chemotherapy, nodal involvement or PD-L1 status. months [95% Confidence Interval (CI): 16.5 months [95% CI: 8.3 to 13.9]). to 13.9]).
Let's personalize your content